Myriad wins diagnostics IP case

Myriad Genetics ($MYGN) scored a win with a federal court's ruling that the company's claims on genes that predict risk of breast and ovarian cancers can be patented, bringing a close to the company's lengthy battle to secure its intellectual property and encouraging biotechs with heavy interests in genetic research. Report

Like what you're reading?
Click here to get more news like this delivered to your inbox every day >>

Suggested Articles

The randomized, blinded study showed statistically significant improvements in assessments of inattention and brain activity.

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.